#Achillion Pharmaceuticals

The Phase IIb trial investigated the safety and efficacy of the JNJ-4178 regimen, which includes odalasvir, AL-335 and Olysio.

Highlights from research presented at the 52nd International Liver Congress in Amsterdam

The joint venture between the two companies will push the three-drug Olysio/odalasvir/AL-335 into further development.

Achillion has released new data showing excellent results from six weeks of treatment with company’s odalasvir and Gilead’s sofosbuvir.

ACH-3102, a hepatitis C drug under development by Achillion Pharmaceuticals, has received Fast Track status from the FDA, according to an...

The US Food and Drug Administration (FDA) has assigned the Fast Track designation to Achillion Pharmaceuticals, Inc.’s ACH-1625, a drug being...